PET/MRI与PET/CT在肿瘤学中的前瞻性单中心研究:对患者管理的影响与成本考量
该前瞻性单中心研究纳入263例癌症患者共330次同日PET/CT与PET/MRI检查,发现PET/MRI诊断准确率97.3%显著高于PET/CT的83.9%(P<0.001),且8.0%患者因PET/MRI额外发现(主要为肝、脑转移)改变了管理。PET/MRI每次检查成本约高50%,基于组织学的分诊可能合理。
要点
- PET/MRI诊断准确率97.3%显著优于PET/CT的83.9%(P<0.001)。
- 8.0%患者因PET/MRI额外发现(肝、脑转移)改变临床管理。
- PET/MRI每次检查成本596.97欧元,较PET/CT的405.95欧元高约50%。
核心结论
- PET/MRI在不可忽略比例的癌症患者中比PET/CT实现了更恰当的管理。
- 鉴于PET/MRI每次检查成本约高50%,基于组织学的患者分诊至PET/MRI或PET/CT可能有意义。
研究设计与样本
- 前瞻性单中心研究,癌症患者接受常规分期或随访时连续进行同日PET/CT和PET/MRI。
- 共纳入263例患者(330次同日PET/CT和PET/MRI检查),根据肿瘤组织学使用单次给药的[18F]FDG、[68Ga]Ga-DOTANOC或[18F]FDOPA。
- PET/MRI和PET/CT分别评分,按解剖区域评估病灶,基于区域确定每次检查和每例患者的准确率。
- 以模拟多学科团队会议为参考标准,判断PET/CT与PET/MRI的差异是否影响患者管理。
- 使用McNemar检验比较准确率,并计算PET/MRI的增量成本效果比(ICER)。
主要发现
- PET/MRI在319/330次检查中准确,PET/CT在277/330次检查中准确,准确率分别为97.3%和83.9%,差异显著(P<0.001)。
- PET/MRI的额外发现(主要为肝和脑转移)对21/263例患者(8.0%)的患者管理有影响。
- 每次检查成本PET/MRI为596.97欧元,PET/CT为405.95欧元。
- PET/MRI的ICER为每诊断准确率百分点14.26欧元,每正确管理患者百分点23.88欧元。
关键数值与推荐
- PET/MRI诊断准确率97.3%(319/330次检查),PET/CT为83.9%(277/330次检查),P<0.001。
- PET/MRI额外发现影响患者管理在21/263例患者(8.0%)。
- 每次检查成本:PET/MRI 596.97欧元,PET/CT 405.95欧元。
- ICER:每诊断准确率百分点14.26欧元,每正确管理患者百分点23.88欧元。
临床怎么用
- PET/MRI可在部分癌症患者中提供比PET/CT更准确的分期并改变管理,尤其需关注肝、脑转移的检出。
- 考虑PET/MRI成本较高,可根据肿瘤组织学对患者进行分诊,选择PET/MRI或PET/CT。
局限性
- 研究为单中心设计,结果外推需谨慎。
- 参考标准为模拟多学科团队会议,非真实临床结局。
- 成本分析基于特定医疗环境,经济评估的普适性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: PET/MRI has recently been introduced into clinical practice. We prospectively investigated the clinical impact of PET/MRI compared with PET/CT, in a mixed population of cancer patients, and performed an economic evaluation of PET/MRI. METHODS: Cancer patients referred for routine staging or follow-up by PET/CT underwent consecutive PET/CT and PET/MRI, using single applications of [18F]FDG, [68Ga]Ga-DOTANOC, or [18F]FDOPA, depending on tumor histology. PET/MRI and PET/CT were rated separately, and lesions were assessed per anatomic region; based on regions, per-examination and per-patient accuracies were determined. A simulated, multidisciplinary team meeting served as reference standard and determined whether differences between PET/CT and PET/MRI affected patient management. The McNemar tests were used to compare accuracies, and incremental cost-effectiveness ratios (ICERs) for PET/MRI were calculated. RESULTS: Two hundred sixty-three patients (330 same-day PET/CT and PET/MRI examinations) were included. PET/MRI was accurate in 319/330 examinations and PET/CT in 277/330 examinations; the respective accuracies of 97.3% and 83.9% differed significantly (P < 0.001). The additional findings on PET/MRI-mainly liver and brain metastases-had implications for patient management in 21/263 patients (8.0%). The per-examination cost was 596.97 EUR for PET/MRI and 405.95 EUR for PET/CT. ICERs for PET/MRI were 14.26 EUR per percent of diagnostic accuracy and 23.88 EUR per percent of correctly managed patients. CONCLUSIONS: PET/MRI enables more appropriate management than PET/CT in a nonnegligible fraction of cancer patients. Since the per-examination cost is about 50% higher for PET/MRI than for PET/CT, a histology-based triage of patients to either PET/MRI or PET/CT may be meaningful.
引用
- Mayerhoefer ME, Prosch H, Beer L, et al. PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations. Eur J Nucl Med Mol Imaging. 2019. PMID: 31410538. doi:10.1007/s00259-019-04452-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。